Taxus Cardium Pharmaceuticals Stock Price - CRXM

Best deals to access real time data!
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN
Taxus Cardium Pharmaceuticals Group, Inc. (PL) CRXM Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  +0 +0% 0.15114 - - - 0.15114 07:54:06
Bid Price Ask Price Spread Spread % News
0.12 0.1719 0.0519 30.19% - -
Last Trade Time Type Quantity Stock Price Currency
- - - USD

Taxus Cardium Pharmaceuticals Group, Inc. (PL) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.16M 14.27M $ -2.92M - -0.74 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Taxus Cardium Pharmaceuticals Group, Inc. (PL) News

Latest CRXM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRXM Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.1510.17190.090.1699042k11k0.000140.09%
1 Month0.140.17190.090.1658042k5k0.011147.96%
3 Months0.17120.1980.08960.1660049k7k-0.02006-11.72%
6 Months0.20.23990.08920.1708049k6k-0.04886-24.43%
1 Year0.26510.2910.01050.19340351k13k-0.11396-42.99%
3 Years0.42580.630.01050.23650351k15k-0.27466-64.50%
5 Years0.70.790.01050.33820394k17k-0.54886-78.41%

Taxus Cardium Pharmaceuticals Group, Inc. (PL) Description

Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the Company's in-house MedPodium Health Sciences healthy lifestyle product platform. The Company's lead commercial product Excellagen(R) topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx(R) is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.